A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer|Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Pembrolizumab|DRUG: Olaparib|RADIATION: Radiation
Sponsor: Memorial Sloan Kettering Cancer Center